Collaboration Between Kenox and Strides Pharmaceuticals
Recently, Kenox Pharmaceuticals Inc. has embarked on an exciting journey by entering into a strategic product development partnership with Strides Pharma Science Ltd. This collaboration is set to enhance the product pipeline of nasal spray formulations across a variety of therapeutic areas, aligning with both companies' commitment to improving patient care.
Accelerating Nasal Spray Product Development
Kenox, known for its expertise in Orally Inhaled and Nasal Drug Products (OINDPs), will play a pivotal role in providing formulation and development know-how for developing new nasal spray products. This partnership is crucial as it aims to accelerate the availability of affordable, high-quality medicines for the US market, directly impacting patient accessibility and care.
What the Partnership Entails
The collaboration between Kenox and Strides will focus on several key aspects. While specific product details remain confidential for now, the development process will include the creation and regulatory filings necessary for multiple nasal spray products targeted at diverse therapeutic indications. This strategic alliance not only showcases both companies’ strengths but also reinforces their commitment to delivering innovative healthcare solutions.
Expert Insights on the Partnership
Dr. Sitaram Velaga, the Founder, President, and CEO of Kenox Pharmaceuticals, expressed his enthusiasm about this strategic partnership, calling it a significant milestone for Kenox. He remarked, "This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price. Furthermore, this milestone accelerates Kenox's growth plans." This perspective highlights the potential impact of the collaboration on future innovations in healthcare.
Strides’ Vision for Nasal Spray Technology
Aditya Kumar, Executive Director of Business Development at Strides Pharma Science, also shared his thoughts, stating, "We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain." His insights underline Strides' proactive approach to expanding its nasal spray technology capabilities and the natural fit it provides within their overall strategic framework for growth.
About Kenox Pharmaceuticals
Founded in 2018 and based in Greater Princeton, NJ, Kenox is dedicated to pharmaceutical aerosol product development, which includes several formats such as soft mist inhalers (SMIs), dry powder inhalers (DPIs), nebulizers, and nasal sprays. As a contract development organization, Kenox offers comprehensive expertise in formulation design, compounding, fill and finish processes, and testing that adheres to strict compliance standards.
About Strides Pharma Science
Strides Pharma Science Limited operates as a global pharmaceutical company based in Bengaluru, India. The company's business strategy emphasizes growth in regulated markets, focusing specifically on "difficult to manufacture" products. Strides has established an institutional business to cater to donor-funded markets, ensuring a wide reach of its pharmaceutical solutions. With global manufacturing sites across various countries, Strides remains committed to delivering high-quality pharmaceuticals that meet the needs of patients in over 100 countries.
Frequently Asked Questions
What is the purpose of the partnership between Kenox and Strides?
The partnership aims to develop and accelerate the availability of affordable nasal spray products for the US market.
What expertise does Kenox bring to the partnership?
Kenox provides deep expertise in formulation and development related to Orally Inhaled and Nasal Drug Products (OINDPs).
What is Strides known for in the pharmaceutical industry?
Strides is recognized for its focus on difficult-to-manufacture products and its global presence in regulated markets.
How does this collaboration benefit patients?
By enhancing the pipeline of nasal sprays, the collaboration aims to offer patients affordable and high-quality therapeutic options.
When was Kenox established?
Kenox was established in 2018 and is based in Greater Princeton, NJ.
